Metraipolis › archive › dc_911eff73cc50

Safety Profile of Zavegepant in the Treatment of Acute Migraine: Insights from the FDA Adverse Event Monitoring System Database — Europe PMC PMID:42356560

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/42356560
DOI: 10.3390/ph19060943
License (as archived): solo-consultazione
Archived: 2026-10-31T11:07:16.291Z
SHA-256 of the archived text: 82849fc67c6f74073c3a323a8f4efe96fe971b3f04a481e74788d3ef1c12152b
Stable URL of this page: https://metraipolis.com/documento/dc_911eff73cc50

How to cite

Safety Profile of Zavegepant in the Treatment of Acute Migraine: Insights from the FDA Adverse Event Monitoring System Database — Europe PMC PMID:42356560 — Europe PMC (en), https://europepmc.org/article/MED/42356560 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_911eff73cc50 (Metraipolis archive dc_911eff73cc50, sha256 82849fc67c6f74073c3a323a8f4efe96fe971b3f04a481e74788d3ef1c12152b)

BibTeX

@misc{dc911eff73cc50,
  title = {Safety Profile of Zavegepant in the Treatment of Acute Migraine: Insights from the FDA Adverse Event Monitoring System Database — Europe PMC PMID:42356560},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42356560},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_911eff73cc50; sha256 82849fc67c6f74073c3a323a8f4efe96fe971b3f04a481e74788d3ef1c12152b},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42356560. Agents can read the archived copy with the MCP tool read_document.